Sayre promotes novel and / or differentiated medicines in-licensed from global pharmaceutical and biotech companies. Sayre focuses on niche products and orphan medications, in areas with a high unmet need and sub-optimal treatment options, in the Indian sub-continent. These will include but will not be limited to small molecules, recombinant proteins and monoclonal antibodies (mAbs) in Oncology and Immunology.
There are more than 800-900 compounds in development in Oncology and Immunology and together constitute the hottest research areas due to need for improved treatment options. There are more than 40,000 trials listed on the US clinicaltrials.gov site, with more than 40% of the trials in Oncology. Traditional drugs not ideal for long-term use and there is a marked shift towards biologics for chronic long-term usage for immunological conditions.